FR08C0013I1 - - Google Patents

Info

Publication number
FR08C0013I1
FR08C0013I1 FR08C0013C FR08C0013I1 FR 08C0013 I1 FR08C0013 I1 FR 08C0013I1 FR 08C0013 C FR08C0013 C FR 08C0013C FR 08C0013 I1 FR08C0013 I1 FR 08C0013I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911183.3A external-priority patent/GB9911183D0/en
Priority claimed from GBGB9911346.6A external-priority patent/GB9911346D0/en
Priority claimed from GBGB9918534.0A external-priority patent/GB9918534D0/en
Priority claimed from GBGB9927005.0A external-priority patent/GB9927005D0/en
Priority claimed from GBGB9927106.6A external-priority patent/GB9927106D0/en
Priority claimed from GB0007637A external-priority patent/GB0007637D0/en
Application filed filed Critical
Publication of FR08C0013I1 publication Critical patent/FR08C0013I1/fr
Application granted granted Critical
Publication of FR08C0013I2 publication Critical patent/FR08C0013I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
FR08C0013C 1999-05-13 2008-04-16 Utilisation de et743 en thérapie combinée avec dexaméthasone pour traiter le cancer Active FR08C0013I2 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9911183.3A GB9911183D0 (en) 1999-05-13 1999-05-13 Treatment of cancers
GBGB9911346.6A GB9911346D0 (en) 1999-05-14 1999-05-14 Treatment of cancers
GBGB9918534.0A GB9918534D0 (en) 1999-08-05 1999-08-05 Treatment of cancers
GBGB9927005.0A GB9927005D0 (en) 1999-11-15 1999-11-15 Treatment of cancers
GBGB9927106.6A GB9927106D0 (en) 1999-11-16 1999-11-16 Cancer treatment
GB0007637A GB0007637D0 (en) 2000-03-29 2000-03-29 Antitumour compound
EP00927584A EP1176964B8 (en) 1999-05-13 2000-05-15 Uses of et743 for treating cancer

Publications (2)

Publication Number Publication Date
FR08C0013I1 true FR08C0013I1 (enExample) 2008-05-30
FR08C0013I2 FR08C0013I2 (fr) 2009-10-30

Family

ID=27546594

Family Applications (1)

Application Number Title Priority Date Filing Date
FR08C0013C Active FR08C0013I2 (fr) 1999-05-13 2008-04-16 Utilisation de et743 en thérapie combinée avec dexaméthasone pour traiter le cancer

Country Status (32)

Country Link
US (1) US8119638B2 (enExample)
EP (3) EP1702618B1 (enExample)
JP (2) JP2002544231A (enExample)
KR (1) KR20020019914A (enExample)
CN (2) CN100477993C (enExample)
AR (1) AR028476A1 (enExample)
AT (3) ATE375795T1 (enExample)
AU (2) AU777417B2 (enExample)
BG (1) BG65680B1 (enExample)
BR (1) BR0010531A (enExample)
CA (1) CA2373794C (enExample)
CY (4) CY1105818T1 (enExample)
CZ (1) CZ301482B6 (enExample)
DE (4) DE122008000013I1 (enExample)
DK (3) DK1716853T3 (enExample)
ES (2) ES2272279T3 (enExample)
FR (1) FR08C0013I2 (enExample)
HU (2) HU229866B1 (enExample)
IL (2) IL146434A0 (enExample)
LU (1) LU91418I2 (enExample)
MX (1) MXPA01011562A (enExample)
MY (1) MY164077A (enExample)
NL (1) NL300337I2 (enExample)
NO (2) NO324564B1 (enExample)
NZ (1) NZ515423A (enExample)
PL (1) PL198185B1 (enExample)
PT (3) PT1176964E (enExample)
SI (3) SI1702618T1 (enExample)
SK (1) SK287580B6 (enExample)
TR (1) TR200103819T2 (enExample)
UA (1) UA74782C2 (enExample)
WO (1) WO2000069441A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
WO2002036135A2 (en) * 2000-11-06 2002-05-10 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
PL368458A1 (en) * 2001-10-19 2005-03-21 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
JP2007511499A (ja) * 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー コンビネーション
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
JP2007511509A (ja) * 2003-11-14 2007-05-10 ファルマ・マール・ソシエダード・アノニマ Et−743およびパクリタキセルの使用を含むガンの併用療法
JP2008505862A (ja) * 2004-07-09 2008-02-28 ファルマ、マール、ソシエダード、アノニマ 予後分子マーカー
RS50822B (sr) * 2004-10-26 2010-08-31 Pharma Mar S.A., Sociedad Unipersonal Pegilovani lipozomalni doksorubicin u kombinaciji sa ekteinescidinom 743
KR101188691B1 (ko) * 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
WO2007134203A2 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin
WO2009050303A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for et-743 treatment
RU2738741C2 (ru) * 2016-02-04 2020-12-16 Цзянсу Хэнжуй Медицин Ко., Лтд. Инъекционная фармацевтическая композиция, включающая трабектедин, для применения вне желудочно-кишечного тракта и способ её получения
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
CN112574234B (zh) * 2019-09-27 2022-05-24 江苏恒瑞医药股份有限公司 一种海鞘素衍生物的制备方法
CA3176956A1 (en) 2020-04-15 2021-10-21 Ever Valinject Gmbh Composition comprising trabectedin and an amino acid
EP3960177A1 (en) * 2020-08-26 2022-03-02 Anturec Pharmaceuticals GmbH Composition comprising ttf-ngr for use in treating soft-tissue sarcoma
IL308389A (en) * 2021-05-19 2024-01-01 Pharma Mar Sa Dosing regimens for acubactadine
US12303506B2 (en) 2022-01-20 2025-05-20 Extrovis Ag Trabectedin composition

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
EP0309477B1 (en) * 1986-06-09 1991-11-06 The Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
DE3635711A1 (de) 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
GB8805268D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB9101221D0 (en) * 1991-01-19 1991-02-27 Smithkline Beecham Plc Pharmaceuticals
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5891704A (en) * 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
WO1994026250A1 (en) * 1993-05-14 1994-11-24 Depotech Corporation Method for treating neurological disorders
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
EP1920773B1 (en) * 1996-11-05 2011-01-05 The Children's Medical Center Corporation Thalidomide and dexamethasone for the treatment of tumors
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
BR9909488B1 (pt) 1998-04-06 2011-02-08 ecteinascidinas semi-sintéticas e composição farmacêutica.
IL139607A0 (en) * 1998-05-11 2002-02-10 Pharma Mar Sa Metabolites of ecteinascidin 743
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
KR100886496B1 (ko) 2000-04-12 2009-03-05 파르마 마르, 에스.에이. 항종양성 엑티나시딘 유도체
US7247892B2 (en) 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
US20020137663A1 (en) 2000-08-11 2002-09-26 Forman Barry M. The anti-neoplastic agent ET-743 inhibits trans activation by SXR
WO2002036135A2 (en) 2000-11-06 2002-05-10 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
WO2002064843A1 (en) 2001-02-09 2002-08-22 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
AU2002242561A1 (en) 2001-03-30 2002-10-15 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
PL368458A1 (en) 2001-10-19 2005-03-21 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
JP2007511499A (ja) 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー コンビネーション
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
JP2007511509A (ja) 2003-11-14 2007-05-10 ファルマ・マール・ソシエダード・アノニマ Et−743およびパクリタキセルの使用を含むガンの併用療法
JP2008505862A (ja) 2004-07-09 2008-02-28 ファルマ、マール、ソシエダード、アノニマ 予後分子マーカー
WO2006035244A2 (en) 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
RS50822B (sr) 2004-10-26 2010-08-31 Pharma Mar S.A., Sociedad Unipersonal Pegilovani lipozomalni doksorubicin u kombinaciji sa ekteinescidinom 743
KR101188691B1 (ko) 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
JP2009517403A (ja) 2005-11-25 2009-04-30 ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュージャージー Parp−1阻害剤の使用
WO2007134203A2 (en) 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin

Also Published As

Publication number Publication date
LU91418I9 (enExample) 2019-01-02
CY1105818T1 (el) 2011-02-02
NO20015516D0 (no) 2001-11-12
ES2294756T3 (es) 2008-04-01
EP1716853B9 (en) 2011-09-28
FR08C0013I2 (fr) 2009-10-30
IL146434A0 (en) 2002-07-25
AU777417B2 (en) 2004-10-14
TR200103819T2 (tr) 2002-04-22
DK1176964T3 (da) 2007-01-15
KR20020019914A (ko) 2002-03-13
PT1176964E (pt) 2007-01-31
NO324564B1 (no) 2007-11-19
ATE338552T1 (de) 2006-09-15
EP1716853B1 (en) 2011-03-09
LU91418I2 (fr) 2008-05-13
HUS1500001I1 (hu) 2016-08-29
HUP0201187A3 (en) 2002-11-28
AR028476A1 (es) 2003-05-14
CZ301482B6 (cs) 2010-03-17
BG65680B1 (bg) 2009-06-30
US20070275942A1 (en) 2007-11-29
ES2272279T3 (es) 2007-05-01
WO2000069441A1 (en) 2000-11-23
DE60036826D1 (de) 2007-11-29
CN1360503A (zh) 2002-07-24
CA2373794A1 (en) 2000-11-23
SI1176964T1 (sl) 2007-02-28
BR0010531A (pt) 2002-06-04
JP5777562B2 (ja) 2015-09-09
AU2005200180A1 (en) 2005-02-10
DE60030554D1 (de) 2006-10-19
AU4597500A (en) 2000-12-05
CN1679631A (zh) 2005-10-12
EP1176964A1 (en) 2002-02-06
SK16442001A3 (sk) 2002-03-05
BG106171A (en) 2002-06-28
PL352931A1 (en) 2003-09-22
EP1702618A3 (en) 2006-12-27
DE60030554T2 (de) 2007-09-13
AU2005200180B9 (en) 2008-05-29
PL198185B1 (pl) 2008-06-30
NL300337I1 (nl) 2008-05-01
PT1716853E (pt) 2011-05-12
EP1176964B8 (en) 2007-10-10
NZ515423A (en) 2004-04-30
JP2002544231A (ja) 2002-12-24
ATE500830T1 (de) 2011-03-15
EP1702618A2 (en) 2006-09-20
NO2008005I1 (no) 2008-06-09
NO2008005I2 (enExample) 2010-09-27
HU229866B1 (en) 2014-10-28
EP1716853A3 (en) 2006-11-15
CY2008007I1 (el) 2009-11-04
SI1716853T1 (sl) 2011-10-28
CY2008007I2 (el) 2009-11-04
EP1716853A2 (en) 2006-11-02
JP2012149095A (ja) 2012-08-09
MXPA01011562A (es) 2002-07-30
EP1702618B1 (en) 2007-10-17
CA2373794C (en) 2005-10-11
PT1702618E (pt) 2008-01-11
MY164077A (en) 2017-11-30
CY1107143T1 (el) 2010-07-28
DK1702618T3 (da) 2008-02-25
SI1702618T1 (sl) 2008-02-29
DE122008000013I1 (de) 2008-08-07
EP1176964B1 (en) 2006-09-06
US8119638B2 (en) 2012-02-21
UA74782C2 (uk) 2006-02-15
DK1716853T3 (da) 2011-06-27
DE60036826T2 (de) 2008-08-28
CZ20014081A3 (cs) 2002-11-13
ATE375795T1 (de) 2007-11-15
CY1112753T1 (el) 2016-02-10
DE60030554T8 (de) 2008-01-10
IL146434A (en) 2008-03-20
DE60045720D1 (de) 2011-04-21
AU2005200180B2 (en) 2007-12-13
NO20015516L (no) 2002-01-11
SK287580B6 (sk) 2011-03-04
HUP0201187A2 (en) 2002-09-28
CN100477993C (zh) 2009-04-15
NL300337I2 (nl) 2008-09-01

Similar Documents

Publication Publication Date Title
BE2018C020I2 (enExample)
BE2016C007I2 (enExample)
BE2015C018I2 (enExample)
BE2013C020I2 (enExample)
BE2013C001I2 (enExample)
BE2012C036I2 (enExample)
BE1025464I2 (enExample)
BE2008C046I2 (enExample)
BRPI0017527B8 (enExample)
BE2008C047I2 (enExample)
JP2002525159A5 (enExample)
BRPI0001672A2 (enExample)
JP2002506701A5 (enExample)
FR12C0014I1 (enExample)
BRPI0001542A2 (enExample)
NO2008005I2 (enExample)
JP2002533150A5 (enExample)
IN189919B (enExample)
BRPI0012675B8 (enExample)
JP2002526286A5 (enExample)
JP2002530197A5 (enExample)
BRPI0017522A2 (enExample)
HU0004454D0 (enExample)
JP2002530548A5 (enExample)
BRMU7902607U2 (enExample)